QT Imaging Holdings, Inc. QTI

QT Imaging Holdings, Inc. (Nasdaq: QTI) will be honored at Premier’s 2026 Breakthroughs Conference and Exhibition for its FDA-cleared Breast Acoustic CT™ Scanner, a radiation-free imaging system delivering true 3D, quantitative breast images using low-energy sound waves. The award recognizes QT Imaging’s innovative, patient-centered approach to breast health, aiming to provide high-resolution imaging without radiation, compression, or contrast. QT Imaging credits NXC Imaging, Canon Medical Systems USA’s distribution partner, for helping bring the scanner to Premier’s member healthcare organizations. The company describes the technology as an operator-independent platform enabling standardized quantitative assessment and plans to scale manufacturing and expand commercialization globally. The announcement includes customary forward-looking statements and risk disclosures. Premier recognition could enhance credibility and partnerships, but no immediate revenue or regulatory milestones are announced.

QT Imaging Holdings issued its mid-year 2026 CEO letter to shareholders. Mid-year CEO letter delivers company updates that may shift investor sentiment and operational outlook.

QT Imaging Holdings Inc posted 103% revenue growth in Q2 2026 earnings call highlights. 103% revenue surge signals major positive shift in financial trajectory.

QT Imaging Holdings reports strong second quarter growth while advancing preparations for commercial scale operations. Strong quarterly growth combined with commercial scaling steps signals major positive shifts in revenue potential and market position.

QT Imaging Holdings, Inc. (QTI) held its Q2 2026 earnings call. Earnings call delivers quarterly results and outlook that can shift near-term investor views on operations.

QT Imaging Holdings appoints two executives to advance its direct U.S. commercial strategy and accelerate adoption of its Breast Acoustic CT Scanner. Two key hires strengthen commercial execution to expand U.S. adoption of the Breast Acoustic CT Scanner.

QT Imaging Holdings, Inc. obtains regulatory registration from the Israeli Ministry of Health. Israeli regulatory registration opens market access and supports revenue expansion outside the US.

QT Imaging Holdings completed its first FDA routine inspection with zero Form 483 observations. Successful routine FDA inspection confirms compliance and supports operational credibility without altering core strategy.

QT Imaging Holdings sets new reproducibility standard for quantitative biomarkers in breast imaging. New reproducibility standard strengthens QT Imaging's technology leadership in breast imaging.

QT Imaging Holdings, Inc. (QTI) receives Saudi Arabia FDA regulatory clearance. Saudi Arabia clearance enables limited international market expansion for QT Imaging products.

QT Imaging Holdings, Inc. (QTI) will join the Russell Microcap Index as part of the annual reconstitution effective after market close on June 28, 2024. Index inclusion draws passive fund inflows that can lift liquidity and visibility for the microcap stock.

QT Imaging Holdings, Inc. closed a $10 million underwritten public offering. The capital raise directly bolsters QT Imaging Holdings' cash reserves and operational runway.

QT Imaging Holdings, Inc. (QTI) announced the pricing of a $10 million underwritten public offering. $10 million public offering provides substantial capital infusion to support operations and growth.

QT Imaging Holdings Inc (QTI) reported strong revenue growth in its Q1 2026 earnings call highlights amid operational challenges. Strong revenue growth in Q1 2026 indicates significant positive momentum for QTI's financial performance and market sentiment.

QT Imaging Holdings Inc (QTI) released highlights from its Q1 earnings call, covering financial results, operational updates, and forward-looking guidance. Q1 earnings call highlights detail financial performance, revenue growth, and strategic initiatives that significantly influence investor sentiment and market trajectory.

QT Imaging Holdings, Inc. (QTI) released the complete transcript of its Q1 2026 earnings call. Q1 2026 earnings call transcript discloses financial results, guidance, and strategic plans impacting future performance.

QT Imaging Holdings, Inc. (QTI) reported $6.5 million in revenue for the first quarter of 2026. Quarterly revenue reporting affects financial performance and investor sentiment but is one data point among broader factors.

Leading breast surgical oncologist Dr. Barry Roseman appointed as Senior Medical Advisor to QT Imaging Holdings, Inc. (QTI) to guide advancements in breast imaging technology. Appointing a leading breast surgical oncologist as Senior Medical Advisor provides strategic medical expertise that could significantly enhance QT Imaging's credibility, product innovation, and competitive positioning in breast health.

QT Imaging Holdings, Inc. (QTI) debuts the QT Imaging-Olea Viewer, enabling integrated multimodality breast imaging within a single user interface. Debuting an integrated multimodality breast imaging viewer strengthens QTI's product innovation and competitive edge in medical imaging.

QT Imaging Holdings, Inc. (QTI) released its next-generation breast imaging reconstruction software, enhancing image quality, reducing scan times, and improving clinical workflow for breast ultrasound systems. Next-generation software launch advances core breast imaging technology, boosting product competitiveness and market potential.

QT Imaging Holdings Inc (QTI) reported record revenue growth in its Q4 2025 earnings call, highlighting strong financial performance and key operational achievements. Record revenue growth signals major positive shift in financial trajectory and investor sentiment.

QT Imaging Holdings, Inc. (QTI) reported its 2025 fourth quarter and full-year financial results. Full-year and Q4 financial results disclosure significantly affects investor sentiment, stock valuation, and future performance expectations.

QT Imaging Holdings, Inc. (QTI) received regulatory clearance from UAE authorities for its QT Ultrasound breast imaging platform, enabling commercialization and sales in the region and marking a key step in Middle East expansion. UAE regulatory clearance enables entry into a new international market, significantly boosting growth prospects and investor sentiment.

QT Imaging Holdings, Inc. (QTI) received FDA clearance for an enhanced configuration of its Breast Acoustic CT Scanner, designed to improve posterior breast imaging coverage. FDA clearance for an enhanced breast imaging scanner strengthens QTI's product portfolio and competitive edge in medical imaging.

QT Imaging Holdings, Inc. (QTI) appoints renowned breast cancer researcher Dr. Mary Yamashita as Medical Advisor. Appointing a renowned breast cancer researcher strengthens QTI's expertise and competitive positioning in medical imaging without fundamentally transforming operations.

QT Imaging Holdings, Inc. (QTI) achieved a major reimbursement milestone by receiving a Category III CPT code from the American Medical Association (AMA) for its 3D Breast Ultrasound Tomography (CUSE), enabling tracking of clinical use and paving the way for future permanent reimbursement. Category III CPT code approval facilitates insurance billing and clinical adoption of QTI's 3D breast ultrasound technology, significantly enhancing revenue potential and market positioning.

QT Imaging Holdings, Inc. (QTI) announced preliminary unaudited financial results for the fourth quarter and full year 2025. Preliminary annual financial results disclosure significantly impacts investor sentiment, stock price, and future market performance.

QT Imaging Holdings, Inc. (QTI) announced its participation in the SPIE Medical Imaging 2026 conference, where it will present advancements in its imaging technology. The presentation aims to showcase the company's innovative solutions in medical imaging, highlighting its commitment to enhancing diagnostic capabilities. This event is expected to attract attention from industry professionals and potential investors. Participation in a significant industry conference may enhance visibility and influence product innovation.

QT Imaging Holdings, Inc. (QTIH) has partnered with Olea Medical to enhance its cloud imaging platform. This collaboration aims to integrate advanced imaging technologies, improving diagnostic capabilities and streamlining workflows for healthcare providers. The partnership is expected to leverage Olea Medical's expertise in imaging software and QT Imaging's innovative solutions, ultimately enhancing patient care and operational efficiency. The partnership is a significant strategic move that could enhance product offerings and competitive positioning in the healthcare imaging market.

QT Imaging Holdings, Inc. (QTIH) has partnered with Olea Medical to develop a cloud-based breast analytics platform. This collaboration aims to enhance breast imaging analysis, leveraging advanced technology to improve diagnostic accuracy and patient outcomes. The integration of cloud capabilities is expected to streamline workflows for healthcare providers and facilitate better data management in breast cancer detection and treatment. The collaboration with Olea Medical represents a significant strategic move that could enhance QTIH's product offerings and competitive positioning in the healthcare market.